Published in Nat Rev Cancer on November 05, 2015
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open (2016) 0.88
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol (2016) 0.82
Integrative clinical genomics of metastatic cancer. Nature (2017) 0.82
SparkText: Biomedical Text Mining on Big Data Framework. PLoS One (2016) 0.80
Recent Advances of Light-Mediated Theranostics. Theranostics (2016) 0.80
Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps. Oncotarget (2016) 0.78
Fluorescence in situ hybridization in surgical pathology: principles and applications. J Pathol Clin Res (2017) 0.78
Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders. Dialogues Clin Neurosci (2016) 0.77
Tissue-specific tumorigenesis: context matters. Nat Rev Cancer (2017) 0.77
Optimizing mouse models for precision cancer prevention. Nat Rev Cancer (2016) 0.77
Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nat Med (2016) 0.77
Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat Protoc (2017) 0.77
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy. Front Pharmacol (2016) 0.76
Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations. Clin Cancer Res (2017) 0.76
Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. Sci Rep (2017) 0.75
Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. Am J Cancer Res (2016) 0.75
Tissue-based next generation sequencing: application in a universal healthcare system. Br J Cancer (2017) 0.75
Changing paradigm of cancer therapy: precision medicine by next-generation sequencing. Cancer Biol Med (2016) 0.75
Towards the Design of a Patient-Specific Virtual Tumour. Comput Math Methods Med (2016) 0.75
Challenges influencing next generation technologies for precision medicine. Expert Rev Precis Med Drug Dev (2016) 0.75
Integrating functional genomics to accelerate mechanistic personalized medicine. Cold Spring Harb Mol Case Stud (2017) 0.75
Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University. Front Oncol (2016) 0.75
Magnetically Actuated Protease Sensors for in Vivo Tumor Profiling. Nano Lett (2016) 0.75
Light in diagnosis, therapy and surgery. Nat Biomed Eng (2017) 0.75
Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition. Oncogene (2016) 0.75
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer. Am J Cancer Res (2016) 0.75
How to unleash mitochondrial apoptotic blockades to kill cancers? Acta Pharm Sin B (2016) 0.75
The novel long intergenic noncoding RNA UCC promotes colorectal cancer progression by sponging miR-143. Cell Death Dis (2017) 0.75
Toward Precision Healthcare: Context and Mathematical Challenges. Front Physiol (2017) 0.75
Application of Multimodality Imaging Fusion Technology in Diagnosis and Treatment of Malignant Tumors under the Precision Medicine Plan. Chin Med J (Engl) (2016) 0.75
Multi-drug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. Cancer Res (2017) 0.75
Functional precision cancer medicine-moving beyond pure genomics. Nat Med (2017) 0.75
Autophagy and Ferroptosis - What's the Connection? Curr Pathobiol Rep (2017) 0.75
Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. Eur Urol (2017) 0.75
Monitoring drug induced apoptosis and treatment sensitivity in non-small cell lung carcinoma using dielectrophoresis. Biochim Biophys Acta (2016) 0.75
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci (2017) 0.75
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A (2017) 0.75
Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One (2017) 0.75
Distinctive behaviour of live biopsy-derived carcinoma cells unveiled using coherence-controlled holographic microscopy. PLoS One (2017) 0.75
Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer. J Exp Clin Cancer Res (2017) 0.75
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Network biology: understanding the cell's functional organization. Nat Rev Genet (2004) 36.62
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature (2009) 19.18
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Interactome networks and human disease. Cell (2011) 7.16
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology (2011) 6.36
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA (2014) 6.32
Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell (2004) 6.24
The future of immune checkpoint therapy. Science (2015) 5.59
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science (2014) 5.25
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol (2011) 4.59
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol (2015) 4.38
Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (2014) 4.34
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
A proteome-scale map of the human interactome network. Cell (2014) 3.91
Droplet microfluidic technology for single-cell high-throughput screening. Proc Natl Acad Sci U S A (2009) 3.85
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell (2015) 3.56
Inconsistency in large pharmacogenomic studies. Nature (2013) 3.46
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis (2009) 3.35
Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 3.19
Organoid cultures derived from patients with advanced prostate cancer. Cell (2014) 3.12
Organoid models of human and mouse ductal pancreatic cancer. Cell (2014) 2.99
Validating therapeutic targets through human genetics. Nat Rev Drug Discov (2013) 2.94
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature (2014) 2.85
Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell (2015) 2.79
Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 2.76
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res (2013) 2.74
High-content single-cell drug screening with phosphospecific flow cytometry. Nat Chem Biol (2007) 2.54
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell (2012) 2.51
The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med (2013) 2.18
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med (2014) 2.12
Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol (2004) 2.09
Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med (2012) 2.08
Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov (2013) 2.07
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov (2015) 2.07
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res (2012) 2.01
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature (2015) 1.99
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov (2013) 1.93
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A (2009) 1.81
Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood (2013) 1.80
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res (2010) 1.73
American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol (2011) 1.71
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A (2010) 1.55
Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat Med (2010) 1.52
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell (2015) 1.46
Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc Natl Acad Sci U S A (2012) 1.46
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med (2015) 1.44
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs (2007) 1.43
A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci Transl Med (2015) 1.43
Mutational robustness of ribosomal protein genes. Science (2010) 1.41
Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst (1990) 1.40
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res (2015) 1.35
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol (2014) 1.28
BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett (2012) 1.27
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep (2014) 1.25
Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer (2015) 1.21
The molecular portrait of in vitro growth by meta-analysis of gene-expression profiles. Genome Biol (2005) 1.17
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov (2015) 1.15
Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev (2013) 1.11
A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics (2004) 1.10
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun (2015) 1.08
Ibrutinib: first global approval. Drugs (2014) 1.05
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun (2015) 1.01
Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research. Clin Cancer Res (2014) 0.97
Overview of a chemoresponse assay in ovarian cancer. Clin Transl Oncol (2014) 0.96
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov (2015) 0.93
A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer (1991) 0.92
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. Br J Haematol (2013) 0.91
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood (2015) 0.88
"In vitro" 3D models of tumor-immune system interaction. Adv Drug Deliv Rev (2014) 0.88
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLoS One (2013) 0.88
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatr Blood Cancer (2011) 0.87
Peptide microarrays for profiling of serine/threonine kinase activity of recombinant kinases and lysates of cells and tissue samples. Methods Mol Biol (2013) 0.86
A case study of personalized therapy for osteosarcoma. Pediatr Blood Cancer (2013) 0.86
The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol (1995) 0.85
Enhancing reproducibility in cancer drug screening: how do we move forward? Cancer Res (2014) 0.84
2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer (1993) 0.83
Functional profiling of live melanoma samples using a novel automated platform. PLoS One (2012) 0.83
Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer. Nat Commun (2015) 0.83
Idelalisib: first global approval. Drugs (2014) 0.82
Direct chemosensitivity monitoring ex vivo on undissociated melanoma tumor tissue by impedance spectroscopy. Cancer Res (2014) 0.79
Sensor-based cell and tissue screening for personalized cancer chemotherapy. Med Biol Eng Comput (2012) 0.78